Europe — EMA
Ocrevus (Ocrelizumab)
Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a strength/form for intravenous use. It treats multiple sclerosis in adult patients.
Request sourcing
What is Ocrelizumab?
Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a strength/form for intravenous use. It treats multiple sclerosis in adult patients. GNH USA supplies Ocrevus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.
GNH USA supplies Ocrevus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.
What is Ocrelizumab used for?
Ocrevus is a disease-modifying therapy that acts on the immune system to manage multiple sclerosis.
- Relapsing‑remitting multiple sclerosis (RRMS): reduces the frequency of clinical relapses and slows disability progression. - Primary progressive multiple sclerosis (PPMS): delays worsening of neurological function. - Clinically isolated syndrome (CIS) with high risk of conversion to MS: lowers the chance of developing definitive multiple sclerosis.
What are the side effects of Ocrelizumab?
Ocrevus may elicit a range of adverse reactions.
Common Side Effects: - Infusion‑related reactions: cough and … … ... ... ... ... … ... … … … … … - Upper ... ... … … … … … … … … … … … … … … … - … … … … ... … … … … … … … … … … … … - ... … … mechan … … … … … … … … … … … … … … - … … … … … … … … … … … … … … … … - … … … … … … … … ... … … … … … …
Serious or Rare
---\n--- … … … ... ... ... ... ... ... ... ... ... ... ...
